Please use this identifier to cite or link to this item: http://repositorio.unifesp.br/handle/11600/29103
Title: Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort
Authors: Urueta-Robledo, Juan
Ariza, Horacio
Jardim, José Roberto [UNIFESP]
Caballero, Andres
Garcia-Calderon, Andres
Amabile-Cuevas, Carlos F.
Hernandez-Oliva, Gerardo
Vivar-Orozco, Raul
MOX-CB Study Group
Fdn LUSARA
Inst Nacl Enfermedades Resp
Hosp Mi Pueblo
Universidade Federal de São Paulo (UNIFESP)
Clin Reina Sofia
Clin Ricardo Palma
Bayer Mexico
Keywords: chronic bronchitis
moxifloxacin
levofloxacin
Issue Date: 1-Sep-2006
Publisher: W B Saunders Co Ltd
Citation: Respiratory Medicine. London: W B Saunders Co Ltd, v. 100, n. 9, p. 1504-1511, 2006.
Abstract: We compared the efficacy and safety of moxifloxacin and levofloxacin for the treatment of patients with acute exacerbations of chronic bronchitis (AECB) using a prospective, randomized, double blind, parallel-group clinical trial design. A total of 563 patients with AECB were enrolled (437 efficacy-valid) at 34 centers in Mexico, Argentina, Brazil, Colombia, and Peru. Patients were randomized to oral therapy with either moxifloxacin 400 mg once daily for 5 days or levofloxacin 500 mg once daily for 7 days. Clinical success was achieved in 201 out of 221 (91.0%) patients in the moxifloxacin group, and in 203 out of 216 (94.0%) in the levofloxacin group, indicating that moxifloxacin is equivalently effective to levofloxacin. Bacteriologic eradication or presumed eradication was also similar in the two treatment groups: 92.8% in the moxifloxacin group and 93.8% in the levofloxacin group. Nausea was the most common drug-related adverse event in each treatment group. the rate of discontinuation because of adverse events was very low (<= 2%). in conclusion, a 5-day course of moxifloxacin is clinically and bacteriologically equivalent to a 7-day course of levofloxacin in the treatment of patients with AECB. the short treatment duration with moxifloxacin may have compliance advantages over other currently used therapies in the 'real-Life' clinical setting. (c) 2006 Elsevier B.V. All rights reserved.
URI: http://repositorio.unifesp.br/handle/11600/29103
ISSN: 0954-6111
Other Identifiers: http://dx.doi.org/10.1016/j.rmed.2006.01.013
Appears in Collections:Em verificação - Geral

Files in This Item:
File Description SizeFormat 
WOS000239833900003.pdf100.57 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.